A new Covid-19 vaccine fromNovavax Inc. is likely to get its first approval in the U.K., and the company is discussing with U.S. regulators whether trial data from other countries could be part of the shot’s review, Chief Executive Officer Stan Erck said.
The companyannounced late Thursday that the vaccine was effective in big trials in the U.K. and South Africa, though its protective power appeared to be reduced in South Africa, where a worrisome mutation is prevalent. Novavax is still recruiting patients for a trial in the U.S. and Mexico, but the U.S. Food and Drug Administration could consider authorizing the vaccine based on the results from abroad, Erck said in an interview on Bloomberg Television.
“We are hoping we can take that data package to the FDA and have them evaluate our vaccine based on the U.K. data while we are running a phase 3 trial in the U.S.,” Erck said. “We are talking to them. We don’t have a definitive answer yet.”
If regulators review Novavax’s full data and conclude the vaccine is safe and effective, it would give the world another highly potent shot alongside those fromPfizer Inc.,Moderna Inc., andAstraZeneca Plc. Novavax is already working on reformulating its product to be more effective against new strains like the one in South Africa, which alsoproved more challenging in a trial of Johnson & Johnson’s vaccine.
Shares of Gaithersburg, Maryland-based Novavax, which is also developing vaccines for other respiratory illnesses, surged 70% to $228.35 at 11:30 a.m. in New York.
— With assistance by Michael Boyle
Source: Read Full Article